CoChat

The Discovery of Novel Vasopressin V1b Receptor Ligands for Pharmacological, Functional and Structural Investigations

Guillon, G., Derick, S., Pena, A., Cheng, L. L., Stoev, S., Seyer, R., Morgat, J. L., Barberis, C., Gal, C. Serradeil‐Le, Wagnon, J., Manning, M. · 2004 · Journal of Neuroendocrinology
Cited by 35

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Until recently, pharmacological studies dealing with vasopressin receptor isoforms were severely hampered by the lack of selective agonists or antagonists that recognize the pituitary V 1b vasopressin receptor. By contrast, many selective vasopressin‐related compounds are available for characterization of the vasopressor (V 1a) or antidiuretic (V 2) vasopressin receptor subtypes. Recently, SSR149415, a selective nonpeptide molecule, was discovered with nanomolar affinity for mammalian V 1b receptors and good selectivity for the other vasopressin and oxytocin receptor isoforms. This molecule exhibits potent antagonist properties both in vitro and in vivo. We also designed synthetic peptides derived from [deaminocysteine 1,arginine 8]vasopressin (dAVP), modified in position 4 by various amino acid residues. Some of these, d[cyclohexylalanine 4]AVP or d[lysine 4]AVP, have a high affinity and an excellent selectivity for the human V 1b receptor subtype. However, they exhibit a mixed V 1b/V 2 pharmacological profile for the rat vasopressin receptor isoforms. Whatever the species considered, these peptides behave as agonists both in bioassays performed in vitro and in vivo. The d[cyclohexylalanine 4]AVP was tritiated and represents the first selective radiolabelled ligand available for studying the human V 1b receptors. The discovery of these new selective V 1b agonists and V 1b antagonist allows an accurate pharmacological characterization of all the vasopressin receptor isoforms. As emphasized in this review, attention to the vasopressin and oxytocin receptor species differences is of critical importance in studies with all vasopressin and oxytocin ligands.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.0953-8194.2004.01163.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 35

Metadata

Authors
Guillon, G., Derick, S., Pena, A., Cheng, L. L., Stoev, S., Seyer, R., Morgat, J. L., Barberis, C., Gal, C. S., Wagnon, J., & Manning, M.
Venue
Journal of Neuroendocrinology
Publisher
Wiley
Published
2004-04
Volume
16
Issue
4
Pages
356-361
ISSN
  • 0953-8194 (ISSN-L)
  • 1365-2826
OpenAlex
W2030222681
Cited by
35
References
7
FWCI
5.86
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Discovery of Novel Vasopressin V1b Receptor Ligands for Pharmacological, Functional and Structural Investigations. https://app.cochat.ai/papers/10.1111/j.0953-8194.2004.01163.x
The paper
Guillon, G., Derick, S., Pena, A., Cheng, L. L., Stoev, S., Seyer, R., Morgat, J. L., Barberis, C., Gal, C. S., Wagnon, J., & Manning, M. (2004). The Discovery of Novel Vasopressin V1b Receptor Ligands for Pharmacological, Functional and Structural Investigations. Journal of Neuroendocrinology. https://doi.org/10.1111/j.0953-8194.2004.01163.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.